Intrathecal Chemotherapy in Burkitt's Lymphoma

Meningeal involvement with Burkitt lymphoma cells constitutes the most challenging therapeutic problem in the management of Burkitt's tumour. The results of intrathecal chemotherapy with methotrexate or cytosine arabinoside in 55 episodes of malignant pleocytosis in 38 patients with Burkitt...

Full description

Saved in:
Bibliographic Details
Published in:BMJ 1971-08, Vol.3 (5773), p.508-512
Main Authors: Ziegler, J. L., Bluming, A. Z.
Format: Article
Language:English
Subjects:
Adolescent
Burkitt lymphoma
Burkitt Lymphoma - cerebrospinal fluid
Burkitt Lymphoma - drug therapy
Cerebrospinal Fluid - cytology
Chemotherapy
Child
Child, Preschool
Cytarabine - administration & dosage
Disease remission
Dosage
Hospital admissions
Humans
Injections, Spinal
Leukocytosis
Medical treatment
Methotrexate - administration & dosage
Neoplasia
Papers and Originals
Relapse
Subarachnoid space
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Meningeal involvement with Burkitt lymphoma cells constitutes the most challenging therapeutic problem in the management of Burkitt's tumour. The results of intrathecal chemotherapy with methotrexate or cytosine arabinoside in 55 episodes of malignant pleocytosis in 38 patients with Burkitt's tumour are described. The response was complete in nearly all patients after the administration of either agent. Cerebrospinal fluid (C.S.F.) remissions were more prolonged in patients receiving intrathecal methotrexate or cytosine arabinoside daily for four days as opposed to a 10-day schedule. A controlled randomized trial of “prophylactic” intrathecal chemotherapy in patients without malignant cells in the C.S.F. on admission showed no protective effect against the subsequent development of malignant pleocytosis. Future therapeutic approaches are considered in the light of these results.
ISSN:0007-1447
0959-8138
1468-5833
DOI:10.1136/bmj.3.5773.508